1. Maris, J. M., Recent advances in neuroblastoma. N Engl J Med 2010, 362 (23), 2202-11. https://doi.org/10.1056/NEJMra0804577.
2. Mlakar, V.; Jurkovic Mlakar, S.; Lopez, G.; Maris, J. M.; Ansari, M.; Gumy-Pause, F., 11q deletion in neuroblastoma: a review of biological and clinical implications. Mol Cancer 2017, 16 (1), 114. https://doi.org/10.1186/s12943-017-0686-8.
3. Pinto, N. R.; Applebaum, M. A.; Volchenboum, S. L.; Matthay, K. K.; London, W. B.; Ambros, P. F.; Nakagawara, A.; Berthold, F.; Schleiermacher, G.; Park, J. R.; Valteau-Couanet, D.; Pearson, A. D.; Cohn, S. L., Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J Clin Oncol 2015, 33 (27), 3008-17. https://doi.org/10.1200/jco.2014.59.4648.
4. Swift, C. C.; Eklund, M. J.; Kraveka, J. M.; Alazraki, A. L., Updates in Diagnosis, Management, and Treatment of Neuroblastoma. Radiographics 2018, 38 (2), 566-580. https://doi.org/10.1148/rg.2018170132.
5. Peifer, M.; Hertwig, F.; Roels, F.; Dreidax, D.; Gartlgruber, M.; Menon, R.; Krämer, A.; Roncaioli, J. L.; Sand, F.; Heuckmann, J. M.; Ikram, F.; Schmidt, R.; Ackermann, S.; Engesser, A.; Kahlert, Y.; Vogel, W.; Altmüller, J.; Nürnberg, P.; Thierry-Mieg, J.; Thierry-Mieg, D.; Mariappan, A.; Heynck, S.; Mariotti, E.; Henrich, K. O.; Gloeckner, C.; Bosco, G.; Leuschner, I.; Schweiger, M. R.; Savelyeva, L.; Watkins, S. C.; Shao, C.; Bell, E.; Höfer, T.; Achter, V.; Lang, U.; Theissen, J.; Volland, R.; Saadati, M.; Eggert, A.; de Wilde, B.; Berthold, F.; Peng, Z.; Zhao, C.; Shi, L.; Ortmann, M.; Büttner, R.; Perner, S.; Hero, B.; Schramm, A.; Schulte, J. H.; Herrmann, C.; O'Sullivan, R. J.; Westermann, F.; Thomas, R. K.; Fischer, M., Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature 2015, 526 (7575), 700-4. https://doi.org/10.1038/nature14980.
6. Bosse, K. R.; Maris, J. M., Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations. Cancer 2016, 122 (1), 20-33. https://doi.org/10.1002/cncr.29706.
7. London, W. B.; Castel, V.; Monclair, T.; Ambros, P. F.; Pearson, A. D.; Cohn, S. L.; Berthold, F.; Nakagawara, A.; Ladenstein, R. L.; Iehara, T.; Matthay, K. K., Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol 2011, 29 (24), 3286-92. https://doi.org/10.1200/jco.2010.34.3392.
8. Nicolai, S.; Pieraccioli, M.; Peschiaroli, A.; Melino, G.; Raschellà, G., Neuroblastoma: oncogenic mechanisms and therapeutic exploitation of necroptosis. Cell Death Dis 2015, 6 (12), e2010. https://doi.org/10.1038/cddis.2015.354.
9. Park, J. A.; Cheung, N. V., Targets and Antibody Formats for Immunotherapy of Neuroblastoma. J Clin Oncol 2020, 38 (16), 1836-1848. https://doi.org/10.1200/jco.19.01410.
10. Johnsen, J. I.; Dyberg, C.; Wickström, M., Neuroblastoma-A Neural Crest Derived Embryonal Malignancy. Front Mol Neurosci 2019, 12, 9. https://doi.org/10.3389/fnmol.2019.00009.
11. Zafar, A.; Wang, W.; Liu, G.; Wang, X.; Xian, W.; McKeon, F.; Foster, J.; Zhou, J.; Zhang, R., Molecular targeting therapies for neuroblastoma: Progress and challenges. Med Res Rev 2021, 41 (2), 961-1021. https://doi.org/10.1002/med.21750.
12. Du, P.; Zhang, X.; Huang, C. C.; Jafari, N.; Kibbe, W. A.; Hou, L.; Lin, S. M., Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis. BMC Bioinformatics 2010, 11, 587. https://doi.org/10.1186/1471-2105-11-587.
13. Tian, Y.; Morris, T. J.; Webster, A. P.; Yang, Z.; Beck, S.; Feber, A.; Teschendorff, A. E., ChAMP: updated methylation analysis pipeline for Illumina BeadChips. Bioinformatics 2017, 33 (24), 3982-3984. https://doi.org/10.1093/bioinformatics/btx513.
14. Langfelder, P.; Horvath, S., WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 2008, 9, 559. https://doi.org/10.1186/1471-2105-9-559.
15. Love, M. I.; Huber, W.; Anders, S., Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 2014, 15 (12), 550. https://doi.org/10.1186/s13059-014-0550-8.
16. Wu, T.; Hu, E.; Xu, S.; Chen, M.; Guo, P.; Dai, Z.; Feng, T.; Zhou, L.; Tang, W.; Zhan, L.; Fu, X.; Liu, S.; Bo, X.; Yu, G., clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (N Y) 2021, 2 (3), 100141. https://doi.org/10.1016/j.xinn.2021.100141.
17. Hänzelmann, S.; Castelo, R.; Guinney, J., GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 2013, 14, 7. https://doi.org/10.1186/1471-2105-14-7.
18. Ritchie, M. E.; Phipson, B.; Wu, D.; Hu, Y.; Law, C. W.; Shi, W.; Smyth, G. K., limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 2015, 43 (7), e47. https://doi.org/10.1093/nar/gkv007.
19. Friedman, J.; Hastie, T.; Tibshirani, R., Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw 2010, 33 (1), 1-22.
20. Charoentong, P.; Finotello, F.; Angelova, M.; Mayer, C.; Efremova, M.; Rieder, D.; Hackl, H.; Trajanoski, Z., Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade. Cell Rep 2017, 18 (1), 248-262. https://doi.org/10.1016/j.celrep.2016.12.019.
21. Hu, X.; Li, J.; Fu, M.; Zhao, X.; Wang, W., The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther 2021, 6 (1), 402. https://doi.org/10.1038/s41392-021-00791-1.
22. Matthay, K. K.; Maris, J. M.; Schleiermacher, G.; Nakagawara, A.; Mackall, C. L.; Diller, L.; Weiss, W. A., Neuroblastoma. Nat Rev Dis Primers 2016, 2, 16078. https://doi.org/10.1038/nrdp.2016.78.
23. Tolbert, V. P.; Matthay, K. K., Neuroblastoma: clinical and biological approach to risk stratification and treatment. Cell Tissue Res 2018, 372 (2), 195-209. https://doi.org/10.1007/s00441-018-2821-2.
24. Yu, Y.; Zeng, Y.; Xia, X.; Zhou, J. G.; Cao, F., Establishment and Validation of a Prognostic Immune Signature in Neuroblastoma. Cancer Control 2021, 28, 10732748211033751. https://doi.org/10.1177/10732748211033751.
25. Zhou, J. G.; Liang, B.; Jin, S. H.; Liao, H. L.; Du, G. B.; Cheng, L.; Ma, H.; Gaipl, U. S., Development and Validation of an RNA-Seq-Based Prognostic Signature in Neuroblastoma. Front Oncol 2019, 9, 1361. https://doi.org/10.3389/fonc.2019.01361.
26. Klumpp, L.; Sezgin, E. C.; Eckert, F.; Huber, S. M., Ion Channels in Brain Metastasis. Int J Mol Sci 2016, 17 (9). https://doi.org/10.3390/ijms17091513.
27 Tonini, G. P.; Romani, M., Genetic and epigenetic alterations in neuroblastoma. Cancer Lett 2003, 197 (1-2), 69-73. https://doi.org/10.1016/s0304-3835(03)00081-8.
28. Shawraba, F.; Hammoud, H.; Mrad, Y.; Saker, Z.; Fares, Y.; Harati, H.; Bahmad, H. F.; Nabha, S., Biomarkers in Neuroblastoma: An Insight into Their Potential Diagnostic and Prognostic Utilities. Curr Treat Options Oncol 2021, 22 (11), 102. https://doi.org/10.1007/s11864-021-00898-1.
29. Yu, K.; Whitlock, J. M.; Lee, K.; Ortlund, E. A.; Cui, Y. Y.; Hartzell, H. C., Identification of a lipid scrambling domain in ANO6/TMEM16F. Elife 2015, 4, e06901. https://doi.org/10.7554/eLife.06901.
30. Kunzelmann, K.; Ousingsawat, J.; Benedetto, R.; Cabrita, I.; Schreiber, R., Contribution of Anoctamins to Cell Survival and Cell Death. Cancers (Basel) 2019, 11 (3). https://doi.org/10.3390/cancers11030382.
31. Perälä, N.; Sariola, H.; Immonen, T., More than nervous: the emerging roles of plexins. Differentiation 2012, 83 (1), 77-91. https://doi.org/10.1016/j.diff.2011.08.001.
32. Neufeld, G.; Mumblat, Y.; Smolkin, T.; Toledano, S.; Nir-Zvi, I.; Ziv, K.; Kessler, O., The semaphorins and their receptors as modulators of tumor progression. Drug Resist Updat 2016, 29, 1-12. https://doi.org/10.1016/j.drup.2016.08.001.
33. Zaman, T.; Helbig, K. L.; Clatot, J.; Thompson, C. H.; Kang, S. K.; Stouffs, K.; Jansen, A. E.; Verstraete, L.; Jacquinet, A.; Parrini, E.; Guerrini, R.; Fujiwara, Y.; Miyatake, S.; Ben-Zeev, B.; Bassan, H.; Reish, O.; Marom, D.; Hauser, N.; Vu, T. A.; Ackermann, S.; Spencer, C. E.; Lippa, N.; Srinivasan, S.; Charzewska, A.; Hoffman-Zacharska, D.; Fitzpatrick, D.; Harrison, V.; Vasudevan, P.; Joss, S.; Pilz, D. T.; Fawcett, K. A.; Helbig, I.; Matsumoto, N.; Kearney, J. A.; Fry, A. E.; Goldberg, E. M., SCN3A-Related Neurodevelopmental Disorder: A Spectrum of Epilepsy and Brain Malformation. Ann Neurol 2020, 88 (2), 348-362. https://doi.org/10.1002/ana.25809.
34. Klutstein, M.; Nejman, D.; Greenfield, R.; Cedar, H., DNA Methylation in Cancer and Aging. Cancer Res 2016, 76 (12), 3446-50. https://doi.org/10.1158/0008-5472.Can-15-3278.
35. Biggar, K. K.; Li, S. S., Non-histone protein methylation as a regulator of cellular signalling and function. Nat Rev Mol Cell Biol 2015, 16 (1), 5-17. https://doi.org/10.1038/nrm3915.
36. Moore, L. D.; Le, T.; Fan, G., DNA methylation and its basic function. Neuropsychopharmacology 2013, 38 (1), 23-38. https://doi.org/10.1038/npp.2012.112.